← Back to Screener
XORTX Therapeutics Inc. Common Stock (XRTX)
Price$2.44
Favorite Metrics
Price vs S&P 500 (26W)-49.91%
Price vs S&P 500 (4W)1.38%
Market Capitalization$4.16M
All Metrics
Book Value / Share (Quarterly)$0.30
P/TBV (Annual)2.12x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-20.19%
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)-24.82%
Gross Margin (TTM)21.01%
Net Profit Margin (TTM)-2.60%
EPS (TTM)$-0.60
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-0.60
EPS (Annual)$-0.56
ROI (Annual)-125.19%
Gross Margin (Annual)21.01%
Cash / Share (Quarterly)$0.12
ROA (Last FY)-98.99%
EBITD / Share (TTM)$-0.66
ROE (5Y Avg)-78.68%
Operating Margin (TTM)-0.27%
Cash Flow / Share (Annual)$-0.41
P/B Ratio1.45x
P/B Ratio (Quarterly)1.93x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-131.30x
ROA (TTM)-90.54%
EPS Incl Extra (Annual)$-0.56
Current Ratio (Annual)2.11x
Quick Ratio (Quarterly)2.07x
3-Month Avg Trading Volume0.00M
52-Week Price Return-67.95%
Revenue / Employee (TTM)$271
Tangible BV / Share (Quarterly)$0.27
P/S Ratio (Annual)0.00x
Asset Turnover (Annual)2.01x
52-Week High$9.85
EPS Excl Extra (Annual)$-0.56
CapEx CAGR (5Y)38.81%
26-Week Price Return-46.13%
Quick Ratio (Annual)2.07x
13-Week Price Return-32.81%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)2.11x
Enterprise Value$2.194
Asset Turnover (TTM)1.88x
Revenue / Employee (Annual)$271
Inventory Turnover (Annual)4.23x
Pretax Margin (Annual)-0.24%
Cash / Share (Annual)$0.12
3-Month Return Std Dev131.16%
Net Income / Employee (TTM)$-1
ROE (Last FY)-127.43%
Net Interest Coverage (Annual)-0.77x
EPS Basic Excl Extra (Annual)$-0.56
P/FCF (TTM)5.73x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.60
Receivables Turnover (Annual)15.35x
ROI (TTM)-117.76%
P/S Ratio (TTM)0.00x
Revenue / Share (Annual)$29.65
Tangible BV / Share (Annual)$0.27
Price vs S&P 500 (52W)-67.56%
Year-to-Date Return-22.34%
5-Day Price Return-6.56%
EPS Normalized (Annual)$-0.56
ROA (5Y Avg)-57.85%
Net Profit Margin (Annual)-2.60%
Month-to-Date Return6.79%
Cash Flow / Share (TTM)$-4.98
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-0.27%
LT Debt / Equity (Annual)0.13x
ROI (5Y Avg)-77.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.60
P/TBV (Quarterly)2.12x
P/B Ratio (Annual)1.93x
Pretax Margin (TTM)-0.24%
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)-32.87%
Beta0.03x
P/FCF (Annual)38.40x
Revenue / Share (TTM)$29.55
ROE (TTM)-120.33%
52-Week Low$2.42
Analyst Recommendations
Dec 2023
Jan 2024
Feb 2024
Mar 2024
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XRTXXORTX Therapeutics Inc. Common Stock | 0.00x | — | 21.01% | — | $2.44 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
XORTX Therapeutics is a clinical-stage biotechnology company developing therapies for progressive kidney disease by targeting purine and uric acid metabolism. The company is advancing three therapeutic candidates for rare kidney disease indications including ADPKD and Type 2 Diabetic Nephropathy, as well as acute kidney injury associated with respiratory infections. The company aims to slow or reverse chronic kidney disease progression and explore additional indications leveraging its intellectual property.